Vofopitant (GR 205171) is a selective neurokinin-1 (NK1) receptor antagonist primarily utilized in pharmacological research. It effectively blocks the action of substance P, a neuropeptide involved in the vomiting reflex, and has been investigated for its potential to prevent nausea and vomiting, particularly those induced by chemotherapy or post-operative conditions. In research contexts, it serves as a valuable component in antiemetic studies, often combined with other agents like corticosteroids or 5-HT3 antagonists to assess enhanced efficacy. Its evaluation is especially focused on managing acute and delayed phases of chemotherapy-induced nausea and vomiting (CINV), aiming to improve patient comfort during cancer treatment simulations. Additionally, it has been explored in preclinical and early clinical studies for other conditions where substance P plays a role, such as migraine, anxiety disorders, and depression, though these applications remain under investigation and it is not approved for clinical use.